{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:29:39Z","timestamp":1789619379030,"version":"build-2803163510"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Adelaide University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The Bcl-2 inhibitor, Venetoclax, is a notable example of a therapeutic emerging from modern drug development pipelines with structural and physiochemical properties sitting beyond Lipinski\u2019s \u201cRule of 5\u201d. The classification of VTX as a biopharmaceutical classification system (BCS) Class IV compound aligns with its observed low solubility and permeability in the gastrointestinal tract. Its inherent \u201cbrick-dust\u201d properties further limit solubility in lipid delivery vehicles, collectively constraining its maximum potential for oral absorption. With a low fasted oral bioavailability (&lt;\u20095%) and a fivefold positive food effect, a clinical dose of 600\u00a0mg is required daily and is prescribed to patients with a meal to ensure therapeutic efficacy. The impact of critical formulation design parameters on the performance of previously reported formulation strategies such as amorphous solid dispersions, nanocrystals and lipid-based systems will be examined. Mechanistic insight into how bio-enabling strategies improve oral absorption of VTX is provided, including enhanced solubility in lipid vehicles, improved solubilisation upon dispersion, mitigation of the gastrointestinal pH gradient, reduced particle size, amorphous state enhanced-solubility and reduced metabolism. Potential alternative formulation strategies such as inorganic vehicles or advanced lipid-based systems are reviewed, with their capability to enhance VTX\u2019s bioavailability whilst reducing the high clinical dose and dependence on food for optimal absorption. Key silica and polymer selection is necessary for loading VTX mesoporous silica nanoparticles and polymeric nanoparticles. Novel formulation avenues, including solidified self-emulsifying systems, supersaturated self-emulsifying systems, solid-lipid nanoparticles, and nanostructured lipid-carriers, are also explored. Systematic in vitro and in vivo investigations of these formulations can provide essential in vitro-in-vivo correlation insights. Integration of lipid formulation-specific parameters into a physiologically based pharmacokinetics model can facilitate improved clinical translation of lipid-based VTX formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Article highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Venetoclax can benefit from reformulation using novel bio-enabling strategies for enhanced oral absorption<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Rational formulation design can beneficially affect the performance of bio-enabling systems<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Use of advanced lipid-based formulations and\/or inorganic vehicles, can enhance pharmacokinetics and reduce limitations of the current clinical use of venetoclax<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Combining advanced formulation science and modelling is key for clinical success of venetoclax-based lipid formulations<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13346-026-02093-x","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:17:40Z","timestamp":1773145060000},"page":"3116-3136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming the oral delivery challenges of venetoclax: advancing a clinically improved Bcl-2 inhibitor"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7521-2524","authenticated-orcid":false,"given":"Yukta","family":"Hegishte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-7901","authenticated-orcid":false,"given":"Paul","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5401-7535","authenticated-orcid":false,"given":"Clive","family":"Prestidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7633-0562","authenticated-orcid":false,"given":"Kristen","family":"Bremmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"9","key":"2093_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11095-019-2654-z","volume":"36","author":"KTJ Chen","year":"2019","unstructured":"Chen KTJ, Gilabert-Oriol R, Bally MB, Leung AWY. Recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia. Pharm Res. 2019;36(9):125.","journal-title":"Pharm Res"},{"issue":"9","key":"2093_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Venetoclax: first global approval. Drugs. 2016;76(9):979\u201387.","journal-title":"Drugs"},{"key":"2093_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","volume":"61","author":"J Mihalyova","year":"2018","unstructured":"Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R. Venetoclax: a new wave in hematooncology. Exp Hematol. 2018;61:10\u201325.","journal-title":"Exp Hematol"},{"key":"2093_CR4","doi-asserted-by":"publisher","first-page":"1291920","DOI":"10.3389\/fphar.2023.1291920","volume":"14","author":"Q Cao","year":"2023","unstructured":"Cao Q, Wu X, Zhang Q, Gong J, Chen Y, You Y, Shen J, Qiang Y, Cao G. Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review. Front Pharmacol. 2023;14:1291920.","journal-title":"Front Pharmacol"},{"key":"2093_CR5","doi-asserted-by":"crossref","unstructured":"Fairbrother WJ, Leverson JD, Sampath D, Souers AJ. Discovery and development of venetoclax, a selective antagonist of BCL-2. In Fischer J, Klein C, Childers WE, editors. Successful drug discovery. 2019. p. 225\u2013245.","DOI":"10.1002\/9783527814695.ch9"},{"issue":"7","key":"2093_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/13543776.2019.1627327","volume":"29","author":"N Zigart","year":"2019","unstructured":"Zigart N, Casar Z. A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent. Expert Opin Ther Pat. 2019;29(7):487\u201396.","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"2093_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.xphs.2017.09.027","volume":"107","author":"A Emami Riedmaier","year":"2018","unstructured":"Emami Riedmaier A, Lindley DJ, Hall JA, Castleberry S, Slade RT, Stuart P, Carr RA, Borchardt TB, Bow DAJ, Nijsen M. Mechanistic physiologically based pharmacokinetic modeling of the dissolution and food effect of a biopharmaceutics classification system IV compound-the venetoclax story. J Pharm Sci. 2018;107(1):495\u2013502.","journal-title":"J Pharm Sci"},{"issue":"6","key":"2093_CR8","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1097\/HS9.0000000000000912","volume":"7","author":"AH Wei","year":"2023","unstructured":"Wei AH, Roberts AW. BCL2 inhibition: a new paradigm for the treatment of AML and beyond. Hemasphere. 2023;7(6):e912.","journal-title":"Hemasphere"},{"key":"2093_CR9","unstructured":"Therapeutic Goods Administration. Australian public assessment report for venetoclax. 2020. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-venetoclax-201009.pdf ."},{"issue":"5","key":"2093_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13807","volume":"17","author":"AH Salem","year":"2024","unstructured":"Salem AH, Menon RM. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clin Transl Sci. 2024;17(5): e13807.","journal-title":"Clin Transl Sci"},{"key":"2093_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2019.05.008","volume":"142","author":"HD Williams","year":"2019","unstructured":"Williams HD, Ford L, Igonin A, Shan Z, Botti P, Morgen MM, Hu G, Pouton CW, Scammells PJ, Porter CJH, Benameur H. Unlocking the full potential of lipid-based formulations using lipophilic salt\/ionic liquid forms. Adv Drug Deliv Rev. 2019;142:75\u201390.","journal-title":"Adv Drug Deliv Rev"},{"key":"2093_CR12","unstructured":"European Medicines Agency. Assessment report venclyxto.\u00a02016. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/venclyxto-epar-public-assessment-report_en.pdf."},{"issue":"1","key":"2093_CR13","first-page":"75","volume":"10","author":"T Onoue","year":"2024","unstructured":"Onoue T, Matthews AH, Vakilpour A, Kang Y, Lefebvre B, Smith AM, McCurdy SR, Fradley MG, Carver J, Chittams J, Scherrer-Crosbie M. Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines. Cardiooncology. 2024;10(1):75.","journal-title":"Cardiooncology"},{"key":"2093_CR14","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212574","volume":"8","author":"LM Ju\u00e1rez-Salcedo","year":"2019","unstructured":"Ju\u00e1rez-Salcedo LM, Desai V, Dalia S. Venetoclax: evidence to date and clinical potential. Drugs Context. 2019;8: 212574.","journal-title":"Drugs Context"},{"issue":"9","key":"2093_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101178","volume":"4","author":"P Arandjelovic","year":"2023","unstructured":"Arandjelovic P, Kim Y, Cooney JP, Preston SP, Doerflinger M, McMahon JH, Garner SE, Zerbato JM, Roche M, Tumpach C, Ong J, Sheerin D, Smyth GK, Anderson JL, Allison CC, Lewin SR, Pellegrini M. Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice. Cell Rep Med. 2023;4(9): 101178.","journal-title":"Cell Rep Med"},{"key":"2093_CR16","doi-asserted-by":"crossref","unstructured":"Eisenmann ED, Talebi Z, Sparreboom A, Baker SD. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic Clin Pharmacol Toxicol. 2022;130 Suppl 1(Suppl 1):23\u201335.","DOI":"10.1111\/bcpt.13623"},{"key":"2093_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020209","author":"TM Nguyen","year":"2024","unstructured":"Nguyen TM, Joyce P, Ross DM, Bremmell K, Jambhrunkar M, Wong SS, Prestidge CA. Combating acute myeloid leukemia via sphingosine kinase 1 inhibitor-nanomedicine combination therapy with cytarabine or venetoclax. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16020209.","journal-title":"Pharmaceutics"},{"issue":"9","key":"2093_CR18","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s10953-022-01141-7","volume":"51","author":"A Avdeef","year":"2022","unstructured":"Avdeef A, Kansy M. Predicting solubility of newly-approved drugs (2016\u20132020) with a simple ABSOLV and GSE(Flexible-Acceptor) consensus model outperforming random forest regression. J Solution Chem. 2022;51(9):1020\u201355.","journal-title":"J Solution Chem"},{"key":"2093_CR19","doi-asserted-by":"crossref","unstructured":"Lindsley CW. Lipophilicity. In\u00a0Stolerman\u00a0IP, Price LH, editors. Encyclopedia of psychopharmacology,\u00a0Springer Berlin Heidelberg: Berlin, Heidelberg; 2020. p. 905-909.","DOI":"10.1007\/978-3-642-36172-2_7015"},{"key":"2093_CR20","doi-asserted-by":"crossref","unstructured":"Koehl NJ, Henze LJ, Kuentz M, Holm R, Griffin BT. Supersaturated lipid-based formulations to enhance the oral bioavailability of venetoclax. Pharmaceutics. 2020;12(6):564.","DOI":"10.3390\/pharmaceutics12060564"},{"key":"2093_CR21","unstructured":"Vadali LR, Gottumukkala N, Sangvikar Y, Jayachandra SB, Jaldu R. Polymorphic forms of venetoclax. International patent application WO2019135253A1, 11\/7\/2019."},{"key":"2093_CR22","doi-asserted-by":"crossref","unstructured":"Zigart N, Crnugelj M, Ilas J, Casar Z. On the stability and degradation pathways of venetoclax under stress conditions. Pharmaceutics. 2020;12(7):639.","DOI":"10.3390\/pharmaceutics12070639"},{"issue":"4","key":"2093_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jcph.821","volume":"57","author":"AH Salem","year":"2017","unstructured":"Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of Venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol. 2017;57(4):484\u201392.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2093_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/dmd.116.071613","volume":"45","author":"H Liu","year":"2017","unstructured":"Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, Serby M, Vaidyanathan S, Wong SL, Agarwal S, Dunbar M, Sydor J, de Morais SM, Lee AJ. Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor Venetoclax in humans and characterization of its unusual metabolites. Drug Metab Dispos. 2017;45(3):294\u2013305.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"2093_CR25","doi-asserted-by":"publisher","first-page":"e70106","DOI":"10.1111\/cts.70106","volume":"17","author":"J Lee","year":"2024","unstructured":"Lee J, Beers JL, Cheng I, Truong V, Brown Z, Muluneh B, Coombs CC, Jackson KD. Interindividual variability in CYP3A-mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia. Clin Transl Sci. 2024;17(12):e70106.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"2093_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","volume":"83","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017;83(4):846\u201354.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2093_CR27","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s12325-018-0793-y","volume":"35","author":"SK Agarwal","year":"2018","unstructured":"Agarwal SK, Tong B, Bueno OF, Menon RM, Salem AH. Effect of Azithromycin on Venetoclax pharmacokinetics in healthy volunteers: implications for dosing Venetoclax with P-gp inhibitors. Adv Ther. 2018;35(11):2015\u201323.","journal-title":"Adv Ther"},{"issue":"9","key":"2093_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/00498254.2017.1381779","volume":"48","author":"MS Chiney","year":"2018","unstructured":"Chiney MS, Menon RM, Bueno OF, Tong B, Salem AH. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. Xenobiotica. 2018;48(9):904\u201310.","journal-title":"Xenobiotica"},{"key":"2093_CR29","doi-asserted-by":"crossref","unstructured":"Kikuchi R, Shebley M, Bow DAJ, Carr RA, Nijsen M, de Morais SM. In vitro characterization of drug metabolizing enzymes and transporters to enable a mechanistic drug-drug interaction assessment for Venetoclax. Drug Metab Pharmacokinet. 2017;32(1, Supplement): S51\u2013S51.","DOI":"10.1016\/j.dmpk.2016.10.212"},{"issue":"8","key":"2093_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40261-022-01172-4","volume":"42","author":"M Badawi","year":"2022","unstructured":"Badawi M, Chen X, Marroum P, Suleiman AA, Mensing S, Koenigsdorfer A, Schiele JT, Palenski T, Samineni D, Hoffman D, Menon R, Salem AH. Bioavailability evaluation of Venetoclax lower-strength tablets and oral powder formulations to establish interchangeability with the 100 mg tablet. Clin Drug Investig. 2022;42(8):657\u201368.","journal-title":"Clin Drug Investig"},{"issue":"11","key":"2093_CR31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jcph.741","volume":"56","author":"AH Salem","year":"2016","unstructured":"Salem AH, Agarwal SK, Dunbar M, Nuthalapati S, Chien D, Freise KJ, Wong SL. Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol. 2016;56(11):1355\u201361.","journal-title":"J Clin Pharmacol"},{"key":"2093_CR32","unstructured":"Food and Drug Administration (2016) Venclexta prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208573s013lbl.pdf."},{"issue":"2","key":"2093_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ijpharm.2013.04.034","volume":"457","author":"FJO Varum","year":"2013","unstructured":"Varum FJO, Hatton GB, Basit AW. Food, physiology and drug delivery. Int J Pharm. 2013;457(2):446\u201360.","journal-title":"Int J Pharm"},{"key":"2093_CR34","doi-asserted-by":"publisher","first-page":"119069","DOI":"10.1016\/j.ijpharm.2020.119069","volume":"577","author":"HB Schultz","year":"2020","unstructured":"Schultz HB, Meola TR, Thomas N, Prestidge CA. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. Int J Pharm. 2020;577:119069.","journal-title":"Int J Pharm"},{"issue":"2","key":"2093_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1124\/dmd.113.055053","volume":"42","author":"EF Choo","year":"2014","unstructured":"Choo EF, Boggs J, Zhu C, Lubach JW, Catron ND, Jenkins G, Souers AJ, Voorman R. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Drug Metab Dispos. 2014;42(2):207\u201312.","journal-title":"Drug Metab Dispos"},{"key":"2093_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jconrel.2021.12.003","volume":"341","author":"AS Elz","year":"2022","unstructured":"Elz AS, Trevaskis NL, Porter CJH, Bowen JM, Prestidge CA. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. J Control Release. 2022;341:676\u2013701.","journal-title":"J Control Release"},{"issue":"1","key":"2093_CR37","first-page":"188319","volume":"1873","author":"UH Gala","year":"2020","unstructured":"Gala UH, Miller DA, Williams RO 3rd. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochim Biophys Acta (BBA). 2020;1873(1):188319.","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"2093_CR38","doi-asserted-by":"publisher","unstructured":"Bhosale\u00a0DS, Kalshetti\u00a0MS. Enhanced drug dissolution of nitrofurantoin using a solid dispersion technique. BIOI. 2024;5(1). https:\/\/doi.org\/10.15212\/bioi-2024-0025.","DOI":"10.15212\/bioi-2024-0025"},{"issue":"3","key":"2093_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/pharmaceutics10030074","volume":"10","author":"X Zhang","year":"2018","unstructured":"Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics. 2018;10(3):74.","journal-title":"Pharmaceutics"},{"key":"2093_CR40","unstructured":"Vasireddis UMR, Buddepu SR, Dehury SK. Process for preparation of amorphous form of venetoclax. Laurus Labs Ltd: WIPO (PCT); 2017."},{"key":"2093_CR41","doi-asserted-by":"crossref","unstructured":"Haser A, DiNunzio JC, Martin C, McGinity JW, Zhang F. Melt extrusion, In:\u00a0Williams III RO, Watts AB, Miller DA, eds. Formulating poorly water soluble drugs, Springer Cham. 2016. p. 383\u2013435.","DOI":"10.1007\/978-3-319-42609-9_9"},{"issue":"3","key":"2093_CR42","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-01968-1","volume":"22","author":"SG Kala","year":"2021","unstructured":"Kala SG, Chinni S. Development and characterization of venetoclax nanocrystals for oral bioavailability enhancement. AAPS PharmSciTech. 2021;22(3): 92.","journal-title":"AAPS PharmSciTech"},{"key":"2093_CR43","doi-asserted-by":"publisher","first-page":"105497","DOI":"10.1016\/j.ejps.2020.105497","volume":"154","author":"MS Bohsen","year":"2020","unstructured":"Bohsen MS, Elvang PA, Reder-Hilz B, Lenz V, Rosenberg J, Brandl M. (Sub)micron particles forming in aqueous dispersions of amorphous solid dispersions of the poorly soluble drug ABT-199: a combined particle optical counting and field-flow fractionation study. Eur J Pharm Sci. 2020;154:105497.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"2093_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030134","volume":"10","author":"MR Gigliobianco","year":"2018","unstructured":"Gigliobianco MR, Casadidio C, Censi R, Di Martino P. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics. 2018;10(3): 134.","journal-title":"Pharmaceutics"},{"key":"2093_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2018.07.012","volume":"131","author":"R Sverdlov Arzi","year":"2018","unstructured":"Sverdlov Arzi R, Sosnik A. Electrohydrodynamic atomization and spray-drying for the production of pure drug nanocrystals and co-crystals. Adv Drug Deliv Rev. 2018;131:79\u2013100.","journal-title":"Adv Drug Deliv Rev"},{"key":"2093_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2023.100031","volume":"2","author":"ZH Mok","year":"2024","unstructured":"Mok ZH. The effect of particle size on drug bioavailability in various parts of the body. Pharmaceutical Science Advances. 2024;2: 100031.","journal-title":"Pharmaceutical Science Advances"},{"issue":"1","key":"2093_CR47","first-page":"13","volume":"10","author":"VB Junyaprasert","year":"2015","unstructured":"Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 2015;10(1):13\u201323.","journal-title":"Asian J Pharm Sci"},{"issue":"3","key":"2093_CR48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrd2197","volume":"6","author":"CJ Porter","year":"2007","unstructured":"Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231\u201348.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2093_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/pr.112.005660","volume":"65","author":"HD Williams","year":"2013","unstructured":"Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJ. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315\u2013499.","journal-title":"Pharmacol Rev"},{"issue":"1-2","key":"2093_CR50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ijpharm.2013.05.034","volume":"452","author":"YG Seo","year":"2013","unstructured":"Seo YG, Kim DH, Ramasamy T, Kim JH, Marasini N, Oh YK, Kim DW, Kim JK, Yong CS, Kim JO, Choi HG. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm. 2013;452(1\u20132):412\u201320.","journal-title":"Int J Pharm"},{"key":"2093_CR51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/pharmaceutics12070687","volume":"12","author":"R Almasri","year":"2020","unstructured":"Almasri R, Joyce P, Schultz H, Thomas N, Bremmell K, Prestidge C. Porous nanostructure, lipid composition, and degree of drug supersaturation modulate in vitro fenofibrate solubilization in silica-lipid hybrids. Pharmaceutics. 2020;12:687.","journal-title":"Pharmaceutics"},{"issue":"10","key":"2093_CR52","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1021\/acs.molpharmaceut.6b00591","volume":"13","author":"V Bala","year":"2016","unstructured":"Bala V, Rao S, Bateman E, Keefe D, Wang S, Prestidge CA. Enabling oral SN38-based chemotherapy with a combined lipophilic prodrug and self-microemulsifying drug delivery system. Mol Pharm. 2016;13(10):3518\u201325.","journal-title":"Mol Pharm"},{"key":"2093_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119264","volume":"582","author":"HB Schultz","year":"2020","unstructured":"Schultz HB, Wignall AD, Thomas N, Prestidge CA. Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids. Int J Pharm. 2020;582: 119264.","journal-title":"Int J Pharm"},{"key":"2093_CR54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.addr.2016.04.007","volume":"101","author":"OM Feeney","year":"2016","unstructured":"Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, Charman WN, Bergstrom CAS, Porter CJH. 50 years of oral lipid-based formulations: provenance, progress and future perspectives. Adv Drug Deliv Rev. 2016;101:167\u201394.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"2093_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225095","volume":"14","author":"E Jang","year":"2019","unstructured":"Jang E, Son M, Jang J, Lee I-H, Kim S, Kwon T, Jeon Y-h, Koh W-S, Kim K-S, Kim SK. DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy. PLoS ONE. 2019;14(11): e0225095.","journal-title":"PLoS ONE"},{"issue":"3-4","key":"2093_CR56","first-page":"278","volume":"29","author":"CW Pouton","year":"2006","unstructured":"Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Biopharm. 2006;29(3\u20134):278\u201387.","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"2093_CR57","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1080\/03639045.2017.1342654","volume":"43","author":"R Savla","year":"2017","unstructured":"Savla R, Browne J, Plassat V, Wasan KM, Wasan EK. Review and analysis of FDA approved drugs using lipid-based formulations. Drug Dev Ind Pharm. 2017;43(11):1743\u201358.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"2093_CR58","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41597-023-02812-w","volume":"10","author":"J Zaslavsky","year":"2023","unstructured":"Zaslavsky J, Allen C. A dataset of formulation compositions for self-emulsifying drug delivery systems. Sci Data. 2023;10(1):914.","journal-title":"Sci Data"},{"key":"2093_CR59","doi-asserted-by":"crossref","unstructured":"Rajana N, Chary PS, Pooja YS, Bhavana V, Singh H, Guru SK, Singh SB, Mehra NK. Quality by design approach-based fabrication and evaluation of self-nanoemulsifying drug delivery system for improved delivery of venetoclax. Drug Deliv Transl Res. 2024;14:1277\u20131300.","DOI":"10.1007\/s13346-023-01462-0"},{"issue":"12","key":"2093_CR60","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1007\/s11095-013-1126-0","volume":"30","author":"HD Williams","year":"2013","unstructured":"Williams HD, Trevaskis NL, Yeap YY, Anby MU, Pouton CW, Porter CJH. Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion\/absorption pathway. Pharm Res. 2013;30(12):2976\u201392.","journal-title":"Pharm Res"},{"issue":"1","key":"2093_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jconrel.2012.02.027","volume":"160","author":"N Thomas","year":"2012","unstructured":"Thomas N, Holm R, M\u00fcllertz A, Rades T. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J Control Release. 2012;160(1):25\u201332.","journal-title":"J Control Release"},{"key":"2093_CR62","doi-asserted-by":"publisher","first-page":"105452","DOI":"10.1016\/j.ejps.2020.105452","volume":"152","author":"A-R Ilie","year":"2020","unstructured":"Ilie A-R, Griffin BT, Brandl M, Bauer-Brandl A, Jacobsen A-C, Vertzoni M, Kuentz M, Kolakovic R, Holm R. Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapad\u24c7 membrane and in vivo absorption. Eur J Pharm Sci. 2020;152:105452.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"2093_CR63","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1208\/s12248-016-0038-4","volume":"19","author":"SDVS Siqueira","year":"2017","unstructured":"Siqueira SDVS, M\u00fcllertz A, Gr\u00e4eser K, Kasten G, Mu H, Rades T. Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens: in vivo and in vitro evaluations. AAPS J. 2017;19(2):587\u201394.","journal-title":"AAPS J"},{"issue":"6","key":"2093_CR64","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1021\/acs.molpharmaceut.0c00645","volume":"18","author":"NJ Koehl","year":"2021","unstructured":"Koehl NJ, Henze LJ, Bennett-Lenane H, Faisal W, Price DJ, Holm R, Kuentz M, Griffin BT. In silico, in vitro, and in vivo evaluation of precipitation inhibitors in supersaturated lipid-based formulations of Venetoclax. Mol Pharm. 2021;18(6):2174\u201388.","journal-title":"Mol Pharm"},{"issue":"6","key":"2093_CR65","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1021\/acs.molpharmaceut.4c00106","volume":"21","author":"CD Ryan","year":"2024","unstructured":"Ryan CD, Griffin BT, O\u2019Shea JP. Rationalizing counterion selection for the development of lipophilic salts: a case study with Venetoclax. Mol Pharm. 2024;21(6):2981\u201392.","journal-title":"Mol Pharm"},{"issue":"1","key":"2093_CR66","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.xphs.2021.09.008","volume":"111","author":"NJ Koehl","year":"2022","unstructured":"Koehl NJ, Henze LJ, Holm R, Kuentz M, Keating JJ, De Vijlder T, Marx A, Griffin BT. Lipophilic salts and lipid-based formulations for bridging the food effect gap of Venetoclax. J Pharm Sci. 2022;111(1):164\u201374.","journal-title":"J Pharm Sci"},{"key":"2093_CR67","doi-asserted-by":"publisher","first-page":"124108","DOI":"10.1016\/j.ijpharm.2024.124108","volume":"656","author":"A Sirvi","year":"2024","unstructured":"Sirvi A, Jadhav K, Sangamwar AT. Enabling superior drug loading in lipid-based formulations with lipophilic salts for a brick dust molecule: exploration of lipophilic counterions and in vitro-in vivo evaluation. Int J Pharm. 2024;656:124108.","journal-title":"Int J Pharm"},{"key":"2093_CR68","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ejpb.2022.02.002","volume":"172","author":"Y Sumimoto","year":"2022","unstructured":"Sumimoto Y, Okawa S, Inoue T, Masuda K, Maruyama M, Higaki K. Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: disruption of high crystallinity by utilizing its counter ion. Eur J Pharm Biopharm. 2022;172:213\u201327.","journal-title":"Eur J Pharm Biopharm"},{"key":"2093_CR69","doi-asserted-by":"publisher","first-page":"105721","DOI":"10.1016\/j.ejps.2021.105721","volume":"159","author":"S Okawa","year":"2021","unstructured":"Okawa S, Sumimoto Y, Masuda K, Ogawara KI, Maruyama M, Higaki K. Improvement of lipid solubility and oral bioavailability of a poorly water- and poorly lipid-soluble drug, rebamipide, by utilizing its counter ion and SNEDDS preparation. Eur J Pharm Sci. 2021;159:105721.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"2093_CR70","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/1535-7163.MCT-21-0077","volume":"20","author":"AH Salem","year":"2021","unstructured":"Salem AH, Tao ZF, Bueno OF, Chen J, Chen S, Edalji R, Elmore SW, Fournier KM, Harper KC, Hong R, Jenkins GJ, Ji J, Judge RA, Kalvass JC, Klix RC, Ku YY, Leverson JD, Marks RA, Marsh KC, Menon RM, Park CH, Phillips DC, Pu YM, Rosenberg SH, Sanzgiri YD, Sheikh AY, Shi Y, Stolarik D, Suleiman AA, Wang X, Zhang GGZ, Catron ND, Souers AJ. Expanding the repertoire for \u201cLarge Small Molecules\u201d: prodrug ABBV-167 efficiently converts to Venetoclax with reduced food effect in healthy volunteers. Mol Cancer Ther. 2021;20(6):999\u20131008.","journal-title":"Mol Cancer Ther"},{"key":"2093_CR71","doi-asserted-by":"crossref","unstructured":"Valicherla GR, Dave KM, Syed AA, Riyazuddin M, Gupta AP, Singh A, Wahajuddin, Mitra K, Datta D, Gayen JR. Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity. Sci Rep. 2016;6(1):26895.","DOI":"10.1038\/srep26895"},{"key":"2093_CR72","unstructured":"Umeyor C, Ji A, Uronnachi E, Salome Amarachi C, Kenechukwu F, Attama A, Ibezim E. Pharmacokinetics and bio-distribution properties of a self-emulsifying drug delivery system containing nevirapine. J Drug Discov Develop and Deliv. 2020;6(1):1035."},{"issue":"1","key":"2093_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-021-00103-w","volume":"12","author":"AG Vasconcelos","year":"2021","unstructured":"Vasconcelos AG, Barros ALAN, Cabral WF, Moreira DC, da Silva IGM, Silva-Carvalho A\u00c9, de Almeida MP, Albuquerque LFF, dos Santos RC, Brito AKS, Saldanha-Ara\u00fajo F, Arcanjo DDR, Martins MdCC, dos S. Borges TK, B\u00e1o SN, Pl\u00e1cido A, Eaton P, Kuckelhaus SAS, Leite JRSA. Promising self-emulsifying drug delivery system loaded with lycopene from red guava (Psidium guajava L.): in vivo toxicity, biodistribution and cytotoxicity on DU-145 prostate cancer cells. Cancer Nanotechnol. 2021;12(1): 30.","journal-title":"Cancer Nanotechnol"},{"key":"2093_CR74","doi-asserted-by":"publisher","first-page":"120292","DOI":"10.1016\/j.ijpharm.2021.120292","volume":"597","author":"A Lai","year":"2021","unstructured":"Lai A, Sahbaz Y, Ford L, Nguyen TH, Haque S, Williams HD, Benameur H, Scammells PJ, Porter CJH. Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulations. Int J Pharm. 2021;597:120292.","journal-title":"Int J Pharm"},{"issue":"6","key":"2093_CR75","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1021\/mp500790t","volume":"12","author":"Y Sahbaz","year":"2015","unstructured":"Sahbaz Y, Williams HD, Nguyen T-H, Saunders J, Ford L, Charman SA, Scammells PJ, Porter CJH. Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations. Mol Pharm. 2015;12(6):1980\u201391.","journal-title":"Mol Pharm"},{"key":"2093_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121129","author":"RM Moshikur","year":"2021","unstructured":"Moshikur RM, Ali MK, Wakabayashi R, Moniruzzaman M, Goto M. Methotrexate-based ionic liquid as a potent anticancer drug for oral delivery: In vivo pharmacokinetics, biodistribution, and antitumor efficacy. Int J Pharm. 2021. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121129.","journal-title":"Int J Pharm"},{"issue":"4","key":"2093_CR77","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1021\/acsomega.0c04779","volume":"6","author":"HK Saeed","year":"2021","unstructured":"Saeed HK, Sutar Y, Patel P, Bhat R, Mallick S, Hatada AE, Koomoa DT, Lange I, Date AA. Synthesis and characterization of lipophilic salts of Metformin to improve its repurposing for cancer therapy. ACS Omega. 2021;6(4):2626\u201337.","journal-title":"ACS Omega"},{"issue":"3","key":"2093_CR78","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/03639045.2018.1542709","volume":"45","author":"KE Bremmell","year":"2019","unstructured":"Bremmell KE, Prestidge CA. Enhancing oral bioavailability of poorly soluble drugs with mesoporous silica based systems: opportunities and challenges. Drug Dev Ind Pharm. 2019;45(3):349\u201358.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"2093_CR79","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijpharm.2012.09.008","volume":"453","author":"W Xu","year":"2013","unstructured":"Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs. Int J Pharm. 2013;453(1):181\u201397.","journal-title":"Int J Pharm"},{"issue":"2","key":"2093_CR80","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.apsb.2018.01.007","volume":"8","author":"YX Zhou","year":"2018","unstructured":"Zhou YX, Quan GL, Wu QL, Zhang XX, Niu BY, Wu BY, Huang Y, Pan X, Wu CB. Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B. 2018;8(2):165\u201377.","journal-title":"Acta Pharm Sin B"},{"key":"2093_CR81","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.semcancer.2019.08.022","volume":"69","author":"A Barkat","year":"2021","unstructured":"Barkat A, Beg S, Panda SK, K SA, Rahman M, Ahmed FJ. Functionalized mesoporous silica nanoparticles in anticancer therapeutics. Semin Cancer Biol. 2021;69:365\u201375.","journal-title":"Semin Cancer Biol"},{"issue":"25","key":"2093_CR82","doi-asserted-by":"publisher","first-page":"8116","DOI":"10.1021\/ja062286z","volume":"128","author":"F Balas","year":"2006","unstructured":"Balas F, Manzano M, Horcajada P, Vallet-Reg\u00ed M. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc. 2006;128(25):8116\u20137.","journal-title":"J Am Chem Soc"},{"issue":"10","key":"2093_CR83","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1021\/acsbiomaterials.1c00807","volume":"8","author":"CW Ang","year":"2022","unstructured":"Ang CW, Tan L, Qu Z, West NP, Cooper MA, Popat A, Blaskovich MAT. Mesoporous silica nanoparticles improve oral delivery of antitubercular bicyclic nitroimidazoles. ACS Biomater Sci Eng. 2022;8(10):4196\u2013206.","journal-title":"ACS Biomater Sci Eng"},{"issue":"1\u20132","key":"2093_CR84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejps.2012.02.004","volume":"46","author":"V Ambrogi","year":"2012","unstructured":"Ambrogi V, Perioli L, Pagano C, Marmottini F, Ricci M, Sagnella A, Rossi C. Use of SBA-15 for furosemide oral delivery enhancement. Eur J Pharm Sci. 2012;46(1\u20132):43\u20138.","journal-title":"Eur J Pharm Sci"},{"key":"2093_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10040283","author":"AK Meka","year":"2018","unstructured":"Meka AK, Jenkins LJ, D\u00e0valos-Salas M, Pujara N, Wong KY, Kumeria T, Mariadason JM, Popat A. Enhanced solubility, permeability and anticancer activity of Vorinostat using tailored mesoporous silica nanoparticles. Pharmaceutics. 2018. https:\/\/doi.org\/10.3390\/pharmaceutics10040283.","journal-title":"Pharmaceutics"},{"key":"2093_CR86","doi-asserted-by":"publisher","unstructured":"Tripathi M, Bhardwaj P, Tiwari S, Sahu A. The role of biodegradable polymers in nano carrier-based drug delivery system to enhance oral bioavailability & solubility of BCS Class II, IV drugs: a review. 2024. https:\/\/doi.org\/10.20944\/preprints202401.0554.v1.","DOI":"10.20944\/preprints202401.0554.v1"},{"issue":"11","key":"2093_CR87","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s11095-022-03395-8","volume":"39","author":"PS Chary","year":"2022","unstructured":"Chary PS, Rajana N, Devabattula G, Bhavana V, Singh H, Godugu C, Guru SK, Singh SB, Mehra NK. Design, fabrication and evaluation of stabilized polymeric mixed micelles for effective management in cancer therapy. Pharm Res. 2022;39(11):2761\u201380.","journal-title":"Pharm Res"},{"issue":"4","key":"2093_CR88","doi-asserted-by":"publisher","first-page":"617","DOI":"10.15171\/apb.2018.070","volume":"8","author":"S Kumar","year":"2018","unstructured":"Kumar S, Kaur R, Rajput R, Singh M. Bio pharmaceutics classification system (BCS) class IV drug nanoparticles: quantum leap to improve their therapeutic index. Adv Pharm Bull. 2018;8(4):617\u201325.","journal-title":"Adv Pharm Bull"},{"key":"2093_CR89","unstructured":"Soundararajan R. Enhancing the bioavailability of BCS Class IV drugs using polymeric nanoparticles. [Doctoral dissertation, University College London]; 2016."},{"issue":"11","key":"2093_CR90","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1016\/j.apsb.2024.08.027","volume":"14","author":"B Xie","year":"2024","unstructured":"Xie B, Liu Y, Li X, Yang P, He W. Solubilization techniques used for poorly water-soluble drugs. Acta Pharm Sin B. 2024;14(11):4683\u2013716.","journal-title":"Acta Pharm Sin B"},{"key":"2093_CR91","doi-asserted-by":"crossref","unstructured":"Xing H, Wang H, Wu B, Zhang X. Lipid nanoparticles for the delivery of active natural medicines. Curr Pharm Des. 2017;23(43):6705\u20136713.","DOI":"10.2174\/1381612824666171128105853"},{"key":"2093_CR92","doi-asserted-by":"publisher","first-page":"101458","DOI":"10.1016\/j.jddst.2019.101458","volume":"55","author":"S Nasirizadeh","year":"2020","unstructured":"Nasirizadeh S, Malaekeh-Nikouei B. Solid lipid nanoparticles and nanostructured lipid carriers in oral cancer drug delivery. J Drug Deliv Sci Technol. 2020;55:101458.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2093_CR93","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","volume":"133","author":"A Gordillo-Galeano","year":"2018","unstructured":"Gordillo-Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Eur J Pharm Biopharm. 2018;133:285\u2013308.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"2093_CR94","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1208\/s12249-019-1337-8","volume":"20","author":"S Talegaonkar","year":"2019","unstructured":"Talegaonkar S, Bhattacharyya A. Potential of lipid nanoparticles (SLNs and NLCs) in enhancing oral bioavailability of drugs with poor intestinal permeability. AAPS PharmSciTech. 2019;20(3):121.","journal-title":"AAPS PharmSciTech"},{"key":"2093_CR95","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2018.11.006","volume":"142","author":"P Joyce","year":"2019","unstructured":"Joyce P, Dening TJ, Meola TR, Schultz HB, Holm R, Thomas N, Prestidge CA. Solidification to improve the biopharmaceutical performance of SEDDS: opportunities and challenges. Adv Drug Deliv Rev. 2019;142:102\u201317.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"2093_CR96","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s11095-013-1107-3","volume":"30","author":"A Tan","year":"2013","unstructured":"Tan A, Rao S, Prestidge CA. Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance. Pharm Res. 2013;30(12):2993\u20133017.","journal-title":"Pharm Res"},{"issue":"4","key":"2093_CR97","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/pharmaceutics14040831","volume":"14","author":"D Nakmode","year":"2022","unstructured":"Nakmode D, Bhavana V, Thakor P, Madan J, Singh PK, Singh SB, Rosenholm JM, Bansal KK, Mehra NK. Fundamental aspects of lipid-based excipients in lipid-based product development. Pharmaceutics. 2022;14(4):831.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2093_CR98","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2008.10.014","volume":"134","author":"A Tan","year":"2009","unstructured":"Tan A, Simovic S, Davey AK, Rades T, Prestidge CA. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J Control Release. 2009;134(1):62\u201370.","journal-title":"J Control Release"},{"key":"2093_CR99","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.powtec.2018.07.092","volume":"338","author":"P Sharma","year":"2018","unstructured":"Sharma P, Singh SK, Pandey NK, Rajesh SY, Bawa P, Kumar B, Gulati M, Singh S, Verma S, Yadav AK, Wadhwa S, Jain SK, Gowthamarajan K, Malik AH, Gupta S, Khursheed R. Impact of solid carriers and spray drying on pre\/post-compression properties, dissolution rate and bioavailability of solid self-nanoemulsifying drug delivery system loaded with simvastatin. Powder Technol. 2018;338:836\u201346.","journal-title":"Powder Technol"},{"issue":"1","key":"2093_CR100","first-page":"3642418","volume":"2016","author":"H-Y Cho","year":"2016","unstructured":"Cho H-Y, Kang J-H, Ngo L, Tran P, Lee Y-B. Preparation and evaluation of solid-self-emulsifying drug delivery system containing paclitaxel for lymphatic delivery. J Nanomater. 2016;2016(1):3642418.","journal-title":"J Nanomater"},{"issue":"6","key":"2093_CR101","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1248\/cpb.c14-00326","volume":"63","author":"SS Bakhle","year":"2015","unstructured":"Bakhle SS, Avari JG. Development and characterization of solid self-emulsifying drug delivery system of Cilnidipine. Chem Pharm Bull (Tokyo). 2015;63(6):408\u201317.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"4","key":"2093_CR102","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/ph17040500","volume":"17","author":"S Gul","year":"2024","unstructured":"Gul S, Sridhar SB, Jalil A, Akhlaq M, Arshad MS, Sarwar HS, Usman F, Shareef J, Thomas S. Solid self-nanoemulsifying drug delivery systems of Furosemide: in vivo proof of concept for enhanced predictable therapeutic response. Pharmaceuticals. 2024;17(4):500.","journal-title":"Pharmaceuticals"},{"key":"2093_CR103","doi-asserted-by":"crossref","unstructured":"Holm R, Kuentz M, Ilie-Spiridon AR, Griffin BT. Lipid based formulations as supersaturating oral delivery systems: from current to future industrial applications. Eur J Pharm Sci. 2023;189:106556.","DOI":"10.1016\/j.ejps.2023.106556"},{"issue":"1","key":"2093_CR104","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1208\/s12248-012-9433-7","volume":"15","author":"N Thomas","year":"2013","unstructured":"Thomas N, Holm R, Garmer M, Karlsson JJ, M\u00fcllertz A, Rades T. Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. AAPS J. 2013;15(1):219\u201327.","journal-title":"AAPS J"},{"key":"2093_CR105","doi-asserted-by":"publisher","first-page":"106556","DOI":"10.1016\/j.ejps.2023.106556","volume":"189","author":"R Holm","year":"2023","unstructured":"Holm R, Kuentz M, Ilie-Spiridon A-R, Griffin BT. Lipid based formulations as supersaturating oral delivery systems: from current to future industrial applications. Eur J Pharm Sci. 2023;189:106556.","journal-title":"Eur J Pharm Sci"},{"key":"2093_CR106","doi-asserted-by":"publisher","first-page":"105640","DOI":"10.1016\/j.ejps.2020.105640","volume":"157","author":"A M\u00f8ller","year":"2021","unstructured":"M\u00f8ller A, Schultz HB, Meola TR, M\u00fcllertz A, Prestidge CA. The influence of solidification on the in vitro solubilisation of blonanserin loaded supersaturated lipid-based oral formulations. Eur J Pharm Sci. 2021;157:105640.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"2093_CR107","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s13346-020-00853-x","volume":"11","author":"TR Meola","year":"2021","unstructured":"Meola TR, Abuhelwa AY, Joyce P, Clifton P, Prestidge CA. A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants. Drug Deliv Transl Res. 2021;11(3):1261\u201372.","journal-title":"Drug Deliv Transl Res"},{"key":"2093_CR108","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ejps.2016.10.026","volume":"96","author":"R Yasmin","year":"2017","unstructured":"Yasmin R, Rao S, Bremmell K, Prestidge C. Synergistic role of solid lipid and porous silica in improving the oral delivery of weakly basic poorly water soluble drugs. Eur J Pharm Sci. 2017;96:508\u201314.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"2093_CR109","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1002\/jps.23914","volume":"103","author":"R Yasmin","year":"2014","unstructured":"Yasmin R, Tan A, Bremmell KE, Prestidge CA. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations. J Pharm Sci. 2014;103(9):2950\u20139.","journal-title":"J Pharm Sci"},{"key":"2093_CR110","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejpb.2016.05.021","volume":"105","author":"V Bala","year":"2016","unstructured":"Bala V, Rao S, Prestidge CA. Facilitating gastrointestinal solubilisation and enhanced oral absorption of SN38 using a molecularly complexed silica-lipid hybrid delivery system. Eur J Pharm Biopharm. 2016;105:32\u20139.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"2093_CR111","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jconrel.2013.01.012","volume":"167","author":"TH Nguyen","year":"2013","unstructured":"Nguyen TH, Tan A, Santos L, Ngo D, Edwards GA, Porter CJH, Prestidge CA, Boyd BJ. Silica\u2013lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: an in vivo evaluation. J Control Release. 2013;167(1):85\u201391.","journal-title":"J Control Release"},{"issue":"3","key":"2093_CR112","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1021\/mp900063t","volume":"6","author":"S Simovic","year":"2009","unstructured":"Simovic S, Heard P, Hui H, Song Y, Peddie F, Davey AK, Lewis A, Rades T, Prestidge CA. Dry hybrid lipid\u2212silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. Mol Pharm. 2009;6(3):861\u201372.","journal-title":"Mol Pharm"},{"issue":"3","key":"2093_CR113","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1124\/jpet.118.254466","volume":"370","author":"HB Schultz","year":"2019","unstructured":"Schultz HB, Kovalainen M, Peressin KF, Thomas N, Prestidge CA. Supersaturated silica-lipid hybrid oral drug delivery systems: balancing drug loading and in vivo performance. J Pharmacol Exp Ther. 2019;370(3):742\u201350.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"2093_CR114","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11095-020-02955-0","volume":"37","author":"J Brinkmann","year":"2020","unstructured":"Brinkmann J, Exner L, Luebbert C, Sadowski G. In-silico screening of lipid-based drug delivery systems. Pharm Res. 2020;37(12):249.","journal-title":"Pharm Res"},{"issue":"11","key":"2093_CR115","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1016\/j.apsb.2021.04.017","volume":"11","author":"H Gao","year":"2021","unstructured":"Gao H, Jia H, Dong J, Yang X, Li H, Ouyang D. Integrated in silico formulation design of self-emulsifying drug delivery systems. Acta Pharm Sin B. 2021;11(11):3585\u201394.","journal-title":"Acta Pharm Sin B"},{"issue":"8","key":"2093_CR116","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1016\/j.apsb.2021.03.025","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang Y, Yu Q, Chen Z, Wu W, Zhu Q, Lu Y. In vitro and in vivo correlation for lipid-based formulations: current status and future perspectives. Acta Pharm Sin B. 2021;11(8):2469\u201387.","journal-title":"Acta Pharm Sin B"},{"key":"2093_CR117","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejpb.2018.12.010","volume":"136","author":"J Butler","year":"2019","unstructured":"Butler J, Hens B, Vertzoni M, Brouwers J, Berben P, Dressman J, Andreas CJ, Schaefer KJ, Mann J, McAllister M, Jamei M, Kostewicz E, Kesisoglou F, Langguth P, Minekus M, M\u00fcllertz A, Schilderink R, Koziolek M, Jedamzik P, Weitschies W, Reppas C, Augustijns P. In vitro models for the prediction of in vivo performance of oral dosage forms: recent progress from partnership through the IMI OrBiTo collaboration. Eur J Pharm Biopharm. 2019;136:70\u201383.","journal-title":"Eur J Pharm Biopharm"},{"issue":"10","key":"2093_CR118","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, Schlender J-F, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacometrics Syst Pharmacol. 2016;5(10):516\u201331.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2093_CR119","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejpb.2015.07.014","volume":"96","author":"JP O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JP, Faisal W, Ruane-O\u2019Hora T, Devine KJ, Kostewicz ES, O\u2019Driscoll CM, Griffin BT. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: in vitro, in vivo and in silico assessments. Eur J Pharm Biopharm. 2015;96:207\u201316.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"2093_CR120","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ijpharm.2014.06.060","volume":"473","author":"R Berthelsen","year":"2014","unstructured":"Berthelsen R, Sjogren E, Jacobsen J, Kristensen J, Holm R, Abrahamsson B, Mullertz A. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example. Int J Pharm. 2014;473(1\u20132):356\u201365.","journal-title":"Int J Pharm"},{"issue":"10","key":"2093_CR121","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/pharmaceutics17101310","volume":"17","author":"A Bourderi-Cambon","year":"2025","unstructured":"Bourderi-Cambon A, Fadhlaoui K, Garrait G, Lain\u00e9 E, Dhifallah I, Rossano M, Caisse P, Beyssac E. Improving In Vitro\u2013In Vivo Correlation (IVIVC) for lipid-based formulations: overcoming challenges and exploring opportunities. Pharmaceutics. 2025;17(10):1310.","journal-title":"Pharmaceutics"},{"key":"2093_CR122","doi-asserted-by":"crossref","unstructured":"Henze LJ, Koehl NJ, O'Shea JP, Holm R, Vertzoni M, Griffin BT. Combining species specific in vitro & in silico models to predict in vivo food effect in a preclinical stage-case study of Venetoclax. Eur J Pharm Sci. 202;162:105840.","DOI":"10.1016\/j.ejps.2021.105840"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02093-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02093-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02093-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:03:07Z","timestamp":1788357787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02093-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":122,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2093"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02093-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}